Foghorn Therapeutics Inc. Payments to Acquire Marketable Securities
Foghorn Therapeutics Inc. (FHTX) reported Payments to Acquire Marketable Securities of $104.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Foghorn Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $37.08M, a 12.00% decline year-over-year.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $66.94M, a 30.93% increase year-over-year.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $33.98M, a 14.30% decline year-over-year.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $4.00M, a 96.78% decline year-over-year.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for fiscal 2025 was $131.25M, a 49.80% decline from fiscal 2024.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for fiscal 2024 was $261.47M, a 253.81% increase from fiscal 2023.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for fiscal 2023 was $73.90M, a 81.95% decline from fiscal 2022.
- Foghorn Therapeutics Inc. payments to acquire marketable securities for fiscal 2022 was $409.35M, a 309.41% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $104.02M 10-Q · filed 2026-08-06 | $138.00M derived: sum of 3 quarters · filed 2026-08-06 | $142.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $66.94M 10-Q · filed 2026-05-07 | $100.92M derived: sum of 2 quarters · filed 2026-05-07 | $104.92M derived: sum of 3 quarters · filed 2026-05-07 | $147.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $33.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $37.98M derived: sum of 2 quarters · filed 2026-03-11 | $80.12M derived: sum of 3 quarters · filed 2026-08-06 | $131.25M 10-K · filed 2026-03-11 |
| 2025-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $46.14M derived: sum of 2 quarters · filed 2026-08-06 | $97.27M 10-Q · filed 2025-11-05 | $136.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $42.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $93.26M 10-Q · filed 2026-08-06 | $132.91M derived: sum of 3 quarters · filed 2026-08-06 | $257.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $51.12M 10-Q · filed 2026-05-07 | $90.77M derived: sum of 2 quarters · filed 2026-05-07 | $215.23M derived: sum of 3 quarters · filed 2026-05-07 | $281.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $39.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $164.10M derived: sum of 2 quarters · filed 2026-03-11 | $230.21M derived: sum of 3 quarters · filed 2026-03-11 | $261.47M 10-K · filed 2026-03-11 |
| 2024-09-30 | $124.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $190.56M derived: sum of 2 quarters · filed 2025-11-05 | $221.82M 10-Q · filed 2025-11-05 | $228.66M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $66.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $97.37M 10-Q · filed 2025-08-05 | $104.21M derived: sum of 3 quarters · filed 2025-08-05 | $108.07M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $31.26M 10-Q · filed 2025-05-14 | $38.10M derived: sum of 2 quarters · filed 2025-05-14 | $41.96M derived: sum of 3 quarters · filed 2025-05-14 | $78.93M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $10.70M derived: sum of 2 quarters · filed 2025-03-06 | $47.67M derived: sum of 3 quarters · filed 2025-03-06 | $73.90M 10-K · filed 2025-03-06 |
| 2023-09-30 | $3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $40.83M derived: sum of 2 quarters · filed 2024-11-04 | $67.06M 10-Q · filed 2024-11-04 | $111.40M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $36.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $63.20M 10-Q · filed 2024-08-08 | $107.54M derived: sum of 3 quarters · filed 2024-08-08 | $117.16M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $26.23M 10-Q · filed 2024-05-06 | $70.57M derived: sum of 2 quarters · filed 2024-05-06 | $80.19M derived: sum of 3 quarters · filed 2024-05-06 | $223.28M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $44.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $53.96M derived: sum of 2 quarters · filed 2024-03-07 | $197.05M derived: sum of 3 quarters · filed 2024-03-07 | $409.35M 10-K · filed 2024-03-07 |
| 2022-09-30 | $9.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $152.71M derived: sum of 2 quarters · filed 2023-11-02 | $365.01M 10-Q · filed 2023-11-02 | $375.25M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $143.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $355.39M 10-Q · filed 2023-08-04 | $365.63M derived: sum of 3 quarters · filed 2023-08-04 | $412.73M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $212.29M 10-Q · filed 2023-05-08 | $222.54M derived: sum of 2 quarters · filed 2023-05-08 | $269.64M derived: sum of 3 quarters · filed 2023-05-08 | $285.81M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $10.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $57.34M derived: sum of 2 quarters · filed 2023-03-09 | $73.52M derived: sum of 3 quarters · filed 2023-03-09 | $99.98M 10-K · filed 2023-03-09 |
| 2021-09-30 | $47.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $63.27M derived: sum of 2 quarters · filed 2022-11-08 | $89.74M 10-Q · filed 2022-11-08 | $182.72M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $16.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $42.64M 10-Q · filed 2022-08-09 | $135.62M derived: sum of 3 quarters · filed 2022-08-09 | $135.62M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $26.47M 10-Q · filed 2022-05-09 | $119.45M derived: sum of 2 quarters · filed 2022-08-09 | $119.45M derived: sum of 3 quarters · filed 2022-08-09 | $119.45M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $92.98M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $92.98M derived: sum of 2 quarters · filed 2022-08-09 | $92.98M derived: sum of 3 quarters · filed 2022-08-09 | $92.98M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |